CVD_REAL: The Real Benefit of Gliglozins for the Treatment of Type 2 Diabetes in Common Clinical Practice

Abstract

Randomized clinical trials with precisely differentiated patient populations and targets are the gold standard in the evaluation of cardiovascular safety of antidiabetic agents. Differences in the degree of cardiovascular risk among patient populations do not allow unambiguous comparison of these studies among themselves and make it difficult to apply their findings to clinical practice.

Keywords

• CVD-REAL
• meta-analysis
• dapagliflozine
• empagliflozin
• canagliflozin
• cardiovascular complications